TL;DR
This study leverages routinely collected lab data to evaluate adherence to cardiovascular disease (CVD) risk factor screening guidelines. It finds that cholesterol screening guidelines are well-followed, but diabetes screening guidelines could be improved to reduce unnecessary testing and better align with patient progression rates.
What Problem Does This Paper Address?
Cardiovascular disease (CVD) is a leading cause of death globally, and identifying modifiable risk factors like high cholesterol and diabetes early is crucial for prevention. Professional organizations provide guidelines for laboratory screening to detect these conditions. However, it's unclear whether physician practices align with these guidelines and whether the guidelines themselves are optimally timed to catch patient deterioration effectively. This paper investigates this gap by analyzing real-world laboratory data to assess adherence to and the efficacy of current screening guidelines for hypercholesterolemia and type 2 diabetes.
Methods
The researchers utilized the Stanford Translational Research Integrated Database Environment (STRIDE), a large repository of clinical data. They focused on two key laboratory tests: total serum cholesterol and glycated hemoglobin A1c (HbA1c). Two cohorts were created: one for patients with borderline high cholesterol and another for patients with pre-diabetes. The study analyzed two primary metrics:
- Time to retest: The duration between a patient's first pre-disease lab result (borderline cholesterol or pre-diabetes) and their next follow-up test. This was compared against the recommended retest intervals.
- Time to transition: The duration between a patient's first pre-disease lab result and their first result indicating a full disease state (high cholesterol or type 2 diabetes).
Datasets
The study used data from the Stanford Translational Research Integrated Database Environment (STRIDE). This dataset contains information from approximately 2 million pediatric and adult patients, including 25 million clinical encounters, 48 million ICD9-coded diagnoses, and 157 million laboratory test results.
- Cohort 1: 7594 patients with borderline high cholesterol.
- Cohort 2: 2764 patients with pre-diabetes.
No new benchmarks were introduced; the study evaluated existing guidelines against real-world data.
Key Insights and Ideas
- Data-driven guideline evaluation: Routinely collected laboratory data is a powerful tool for assessing the real-world adherence to and effectiveness of clinical guidelines, moving beyond theoretical recommendations.
- Cholesterol guidelines are working: The study highlights that current guidelines for cholesterol screening are generally well-adhered to by physicians, with most patients being retested within the recommended timeframe.
- Diabetes guidelines need refinement: There's a significant disconnect between recommended retesting intervals for pre-diabetes (HbA1c) and actual practice, suggesting potential for both over-testing and delayed identification of progression.
- Adaptive testing potential: The findings suggest that an adaptive testing strategy, where retest intervals are tailored based on individual patient risk and initial test results, could optimize screening efficiency and patient care.
Key Results
- Cholesterol: Over 90% of patients with borderline high cholesterol were retested within the recommended 3-year period. Patients with borderline cholesterol typically progress to high cholesterol within 2-3 years.
- Diabetes: Only about 73% of pre-diabetic patients had their HbA1c retested within the recommended 12-month period. Furthermore, only 48% of these patients transitioned to full type 2 diabetes within that year.
- Progression Rates: Borderline high cholesterol patients are highly likely to transition to hypercholesterolemia within 2-3 years. Pre-diabetic patients transition to type 2 diabetes within 1-2 years, with faster progression observed in those with higher initial test results.
- Proposed Change: The authors suggest extending the recommended retest interval for pre-diabetes to around 1000 days to better align with progression rates and reduce unnecessary testing.
Limitations and Future Work
- Limitations: The study acknowledges that the analysis is a "proof-of-concept" and focuses on only two specific lab tests. The data is from a single institution, which may limit generalizability. The study also notes that physician adherence might be influenced by factors not captured in the data.
- Future Work: The authors propose extending this methodology to other routinely performed screening laboratory tests. They also advocate for the development and implementation of adaptive testing strategies that dynamically adjust retest intervals based on individual patient data and risk factors, aiming to improve efficiency and patient outcomes.
Summary updated